Table 3.
Menopausal Stage and VMS Reporting at Baseline and at Annual Follow-up Visits 5 and 8a
| Visit number | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 5 | 8 | |||||||
| No VMS | VMS 1–5 days | VMS 6+ days | No VMS | VMS 1–5 days | VMS 6+ days | No VMS | VMS 1–5 days | VMS 6+ days | |
| Premenopausal | 842 (68.5%) | 294 (23.9%) | 94 (7.6%) | 44 (62.0%) | 21 (29.6%) | 6 (8.5%) | 10 (55.6%) | 6 (33.3%) | 2 (11.1%) |
| Early perimenopausal | 556 (52.8%) | 342 (32.5%) | 155 (14.7%) | 252 (51.3%) | 163 (33.2%) | 76 (15.5%) | 97 (52.7%) | 58 (31.5%) | 29 (15.8%) |
| Late perimenopausal | 0 | 0 | 0 | 55 (35.5%) | 49 (31.6%) | 52 (32.9%) | 29 (27.4%) | 34 (32.1%) | 43 (40.6%) |
| Postmenopausal | 0 | 0 | 0 | 169 (43.0%) | 106 (27.0%) | 118 (30.0%) | 142 (37.6%) | 125 (33.1%) | 111 (29.4%) |
a
Information regarding VMS (vasomotor symptoms) was obtained annually from baseline to annual follow-up visit 8. Data are presented as n (%).